June 17, 2025
Source: drugdu
55
Heyu announced on the Hong Kong Stock Exchange that its subsidiary Shanghai Heyu Biopharmaceutical Technology Co., Ltd. ("Heyu Pharmaceutical") has completed the first patient dosing in the registration clinical trial of its independently developed highly selective small molecule FGFR4 inhibitor ipagotinib for the treatment of hepatocellular carcinoma (HCC). Ipagotinib was recognized as a breakthrough therapy by the Drug Evaluation Center of the China National Medical Products Administration in May 2025. Ipagotinib is also the first drug to use targeted molecular biomarkers to precisely treat HCC.
https://finance.eastmoney.com/a/202506163430938887.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.